Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

PHASE4CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Age - Related Macular Degeneration (AMD)
Interventions
DRUG

Intravitreal Aflibercept Injection (IAI)

Trial Locations (49)

Unknown

Phoenix

Tucson

Beverly Hills

Oakland

Palm Desert

Sacramento

Santa Ana

Westlake Village

Colorado Springs

Golden

Boynton Beach

Fort Lauderdale

Fort Myers

Pensacola

Plantation

Tampa

Winter Haven

Augusta

Oak Park

New Albany

Wichita

Lexington

Boston

Worcester

Jackson

Lincoln

Las Vegas

Portsmouth

Bloomfield

Lawrenceville

Northfield

Teaneck

Rochester

Asheville

Oklahoma City

Portland

Salem

Kingston

Pittsburgh

Florence

Ladson

West Columbia

Rapid City

Nashville

Arlington

Fort Worth

Houston

San Antonio

Seattle

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01722045 - Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) | Biotech Hunter | Biotech Hunter